ClinConnect ClinConnect Logo
Search / Trial NCT01424722

ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients

Launched by ABBOTT MEDICAL DEVICES · Aug 26, 2011

Trial Information

Current as of August 02, 2025

Terminated

Keywords

Icd Indicated Patients Documented Cad

ClinConnect Summary

This is a prospective, non-randomized, multicenter, pivotal IDE study. The intent of this study is to demonstrate the safety and effectiveness of the ST Monitoring Feature in the Fortify® ST, Fortify Assura® ST, and Ellipse® ST family of devices, as well as any future St Jude Medical devices with the same ST Monitoring Feature capabilities. Effectiveness of the device will be evaluated by analyzing the sensitivity of the ST Monitoring Feature to detect clinical events. In addition, safety of the ST Monitoring Feature will be evaluated by demonstrating a low percentage of patients with false...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Eligible patients will meet all of the following:
  • 1. Have an indication for an ICD implantation or pulse generator change
  • 2. Have documented coronary artery disease. Documented coronary artery disease is defined as having at least one of the following present a) evidence of a prior MI on ECG and/or cardiac enzymes, b) prior revascularization (by coronary artery bypass grafting or percutaneous coronary intervention) c) angina and/or ST-T wave abnormalities indicative of ischemia on exercise stress test, nuclear stress test, or echo stress test, or d) coronary artery disease diagnosed by coronary angiography.
  • 3. Willing and able to comply with protocol requirements, including keeping all required visits
  • 4. Willing to participate in the study and able to sign an IRB approved informed consent form
  • 5. Be at least 18 years of age when enrolled in the study
  • Exclusion Criteria:
  • * Patients will be excluded if they meet any of the following:
  • 1. Are pacemaker dependent (defined as a need for ventricular pacing ≥ 20% of the time)
  • 2. Have NYHA Class IV Heart Failure
  • 3. Have persistent or permanent atrial fibrillation
  • 4. Have a known history of intermittent Bundle Branch Block
  • 5. Pregnant or planning a pregnancy during the study participation
  • 6. Have a life expectancy of \< 1 year due to any condition
  • 7. Are currently participating in a clinical investigation that includes an active treatment arm.

About Abbott Medical Devices

Abbott Medical Devices is a leading global healthcare company dedicated to advancing medical technology through innovative research and development. With a robust portfolio of diagnostic, therapeutic, and monitoring solutions, Abbott is committed to improving patient outcomes and enhancing the quality of care across various medical fields. The company places a strong emphasis on clinical trials to validate the safety and efficacy of its products, ensuring compliance with regulatory standards and fostering collaboration with healthcare professionals. By leveraging cutting-edge science and technology, Abbott Medical Devices aims to address pressing health challenges and deliver transformative solutions that empower patients and healthcare providers alike.

Locations

Rochester, Minnesota, United States

Cleveland, Ohio, United States

Lexington, Kentucky, United States

Traverse City, Michigan, United States

Pittsburgh, Pennsylvania, United States

Spartanburg, South Carolina, United States

Norfolk, Virginia, United States

Washington, District Of Columbia, United States

Winston Salem, North Carolina, United States

Temple, Texas, United States

Orlando, Florida, United States

Honolulu, Hawaii, United States

Fort Lauderdale, Florida, United States

Pittsburgh, Pennsylvania, United States

Louisville, Kentucky, United States

Cleveland, Ohio, United States

Browns Mills, New Jersey, United States

Newark, Delaware, United States

Haddon Heights, New Jersey, United States

Daytona Beach, Florida, United States

Southfield, Michigan, United States

Tyler, Texas, United States

Albuquerque, New Mexico, United States

Greensboro, North Carolina, United States

Los Angeles, California, United States

Ocala, Florida, United States

Elyria, Ohio, United States

Nashville, Tennessee, United States

Los Angeles, California, United States

Little Rock, Arkansas, United States

Glendale, California, United States

Memphis, Tennessee, United States

Rockville, Maryland, United States

Englewood, New Jersey, United States

Toledo, Ohio, United States

Bradenton, Florida, United States

Sacramento, California, United States

West Des Moines, Iowa, United States

New Orleans, Louisiana, United States

Long Beach, California, United States

Gainesville, Georgia, United States

Stony Brook, New York, United States

Greenville, South Carolina, United States

Columbus, Ohio, United States

Fort Wayne, Indiana, United States

Huntsville, Alabama, United States

Ashland, Kentucky, United States

La Jolla, California, United States

Rome, Georgia, United States

Concord, California, United States

Miami, Florida, United States

Tulsa, Oklahoma, United States

Little Rock, Arkansas, United States

Lansing, Michigan, United States

Mesa, Arizona, United States

Hammond, Louisiana, United States

Nashville, Tennessee, United States

Columbus, Ohio, United States

Jackson, Mississippi, United States

Lakeland, Florida, United States

San Antonio, Texas, United States

Bellevue, Washington, United States

Birmingham, Alabama, United States

Buffalo, New York, United States

Jacksonville, Florida, United States

Northridge, California, United States

North Kansas City, Missouri, United States

Sayre, Pennsylvania, United States

Saint Louis, Missouri, United States

Colorado Springs, Colorado, United States

Hershey, Pennsylvania, United States

Chicago, Illinois, United States

Kansas City, Kansas, United States

Worcester, Massachusetts, United States

Ogden, Utah, United States

Camp Hill, Pennsylvania, United States

Johnson City, Tennessee, United States

Columbia, South Carolina, United States

Springfield, Missouri, United States

Birmingham, Alabama, United States

Phoenix, Arizona, United States

Tucson, Arizona, United States

Bakersfield, California, United States

Fullerton, California, United States

Glendale, California, United States

Norwalk, Connecticut, United States

Athens, Georgia, United States

Baltimore, Maryland, United States

Minneapolis, Minnesota, United States

Cherry Hill, New Jersey, United States

Las Cruces, New Mexico, United States

Akron, Ohio, United States

Amarillo, Texas, United States

Dallas, Texas, United States

Richmond, Virginia, United States

Seattle, Washington, United States

Patients applied

0 patients applied

Trial Officials

Michael Gibson, MD

Principal Investigator

Boston Clinical Research Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials